ClinicalTrials.gg
Status unknownNCT04130100Updated Oct 17, 2019

Clinical Study of Pulp Mesenchymal Stem Cells in the Treatment of Primary Mild to Moderate Knee Osteoarthritis

An Early Phase 1 interventional study of Low Dose of Mesenchymal stem cell and High Dose of Mesenchymal stem cell in Knee Osteoarthritis, sponsored by CAR-T (Shanghai) Biotechnology Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-10-17.

Sponsored by CAR-T (Shanghai) Biotechnology Co., Ltd. · Early Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2019), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Apr 2019, registered Oct 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 136 studies in Osteoarthritis, Knee with a site in China — 32 open to participants now, 32 under way, 4 of them phase 3. Osteoarthritis, Knee · China.

Planned enrollment
71st of 115
60 · median 100
Started
2019
with 11 others
Phase 1
10 of 136
6 open now
Registered
63rd of 136
by date

Among the 136 studies in Osteoarthritis, Knee with a site in China, this one is the 71st largest by planned enrollment of the 115 interventional ones that give a count, is one of 12 that started in 2019, is one of 10 in phase 1, and was the 63rd registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

32 of the 136 studies in Osteoarthritis, Knee with a site in China are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies in Osteoarthritis, Knee with a site in China, or all of them as a file.
02

Study summary

To evaluate the clinical efficacy and safety of dental pulp mesenchymal stem cells in the treatment of primary mild to moderate knee osteoarthritis through a comparative study with sodium hyaluronate.

20 participants will receive low dose of dental pulp mesenchymal stem cells, 20 participants will receive high dose and another 20 participants will receive sodium hyaluronate

Read the detailed description

60 participants will receive to evaluate the clinical efficacy and safety of dental pulp mesenchymal stem cells in the treatment of primary mild to moderate knee osteoarthritis through a comparative study with sodium hyaluronate and verify the basis of dental pulp mesenchymal stem cells in the treatment of primary knee osteoarthritis, and to explore a more effective and safe clinical treatment of knee osteoarthritis.

03

Conditions studied

  • Knee Osteoarthritis
04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Complying with the diagnostic criteria for primary knee osteoarthritis revised by the American Rheumatological Association (1995), age 40-70 years, gender-free.
  2. For patients with mild to moderate knee arthritis, the WOMAC score of knee joint was less than 120.
  3. X-ray Kellgren-Lawrence was used to evaluate the grade I, II and III of osteoarthritis.
  4. Fertility patients should take effective measures until the end of follow-up. Fertility women should exclude the possibility of early pregnancy, that is, HCG negative test in early pregnancy.
  5. Voluntary participation in this clinical study, can cooperate with doctors to carry out research, stop all medical measures for knee arthritis for more than 2 weeks, and sign the of patients.

Exclusion criteria

Exclusion Criteria:

(1) Those with other diseases that may affect the knee joint, such as rheumatoid arthritis, ankylosing spondylitis, rheumatoid arthritis, gout and other rheumatic diseases, bone tumors, osteoporosis, bone tuberculosis or obvious history of acute trauma, resulting in meniscus injury, ligament rupture and vascular nerve injury; those with previous history of femur, tibial plateau, tibia and fibula fracture. The patients with gonarthritis, the patients with knee joint and surrounding skin infection were not cured.

  1. Patients who have undergone surgery and other factors affecting the efficacy of the treatment. Patients with severe deformities or even deformities of the knee joint, who need surgical treatment. Patients who have received knee joint irrigation or arthroscopic examination within one year.
  1. Patients with systemic cancer tendency or cancer and patients with systemic infection in active stage.
  1. Patients with severe heart, lung, liver, kidney, blood system, endocrine system and immune deficiency, or abnormal laboratory biochemical indicators, namely: (Hb) \< 9 g/dL, white blood cell (WBC) > 15 x 109/L, (Pt) \< 100 x 109/L, glutamic oxalate transaminase () and alanine aminotransferase (ALT) > 1.5 times normal upper limit; serum creatinine > 1.5 times normal upper limit.
  1. Physical history or clinical manifestations with bleeding tendency, including patients currently using anticoagulants.
  1. Patients with uncontrollable epileptic seizures, psychosis or Alzheimer's disease who are unable to complete the scale.
  1. Pregnant or lactating women, legal disabled patients (blind, deaf, dumb, mentally retarded, physically disabled), drug addiction and other adverse drug addiction.
  1. Patients with or allergies were examined and treated in this study.
  1. Those who have participated in other clinical studies within one month.
  1. Researchers consider it inappropriate for patients to participate in this clinical study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Low Dose of Mesenchymal stem cell

    Patients receiving intraarticular injection of low dose of mesenchymal stem cells.

    Biological: Low Dose of Mesenchymal stem cell

  • Experimental
    High Dose of Mesenchymal stem cell

    Patients receiving intraarticular injection of high dose of mesenchymal stem cells.

    Biological: High Dose of Mesenchymal stem cell

  • Active comparator
    Sodium Hyaluronate

    Patients receiving intraarticular injection of Sodium Hyaluronate

    Drug: Sodium Hyaluronate

Interventions

  • BiologicalLow Dose of Mesenchymal stem cell

    Mesenchymal stem cell injection

    Also known as: 1

  • BiologicalHigh Dose of Mesenchymal stem cell

    Mesenchymal stem cell injection

    Also known as: 2

  • Sodium Hyaluronate injection

    Also known as: 3

06

What researchers measure

Primary outcomes

  1. Kellgren and Lawrence's rating

    X-ray imaging was used to evaluate the degree of improvement in knee joint structure

    Time frame: 12 month

  2. WOMAC score

    WOMAC score decreased

    Time frame: 12 month

Secondary outcomes

  1. Volume of femoral surface of knee joint on MRI

    Changes of volume of lateral femoral condylar, medial femoral condylar, lateral tibial condylar, medial tibial condylar and posterior patellar articular surfaces on MRI

    Time frame: 12 month

  2. relaxation time of femoral surface of knee joint on MRI

    Changes of relaxation time (T1 condylar, T2 condylar, T2\*) of lateral femoral condylar, medial femoral condylar, lateral tibial condylar, medial tibial condylar and posterior patellar articular surfaces on MRI

    Time frame: 12 month

07

Study locations

1 of 1 sites recruiting
  • Changhai hospital
    Shanghai, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2019 (actual). Primary completion is estimated for Sep 2021, 29 months after the start.

Of 34 industry-sponsored phase 1 interventional studies under Osteoarthritis, Knee, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 21. This study's planned 29 months is above that.

Counting every sponsor, half of 61 studies reached it within 20 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2019
First posted
Oct 17, 2019
StartActual
Apr 4, 2019
Primary completionEst.
Sep 30, 2021
CompletionEst.
Dec 30, 2021
Last update
Oct 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04130100
Lead sponsor
CAR-T (Shanghai) Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Oct 17, 2019
Start date
Apr 4, 2019
Primary completion
Sep 30, 2021 (estimated)
Completion
Dec 30, 2021 (estimated)
Last update
Oct 17, 2019

Study contacts

Dongbao Zhao, Doctor
Contact
aolin_521@163.com
+86-18317079530
Dongbao Zhao, Doctor
principal investigator · Changhai Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion